Literature DB >> 10323315

Long-term follow-up and outcome in patients treated for spinal dural arteriovenous fistula.

S Behrens1, A Thron.   

Abstract

Clinical outcome was examined in 21 patients treated for spinal dural arteriovenous fistula after 5-50 months. We compared the neurological condition (motor function, pain, sensory disturbance, vegetative dysfunction) and Barthel index before and after fistula occlusion. Neurological impairment was assessed as improved, unchanged, or deteriorated. All patients initially showed paraparesis of varying degree, and a sensory loss with a defined level in 81% before treatment. The greatest postoperative change that we measured was in motor activity (67% improved), and the most important deterioration was in male potency (28% deteriorated). We observed unchanged or absent symptoms in pain in 71% of our patients. We were thus able not only to stop but even to reverse the progression of symptoms and the degree of disability. On average, neurological symptoms stabilized within 1 year. The results of this study confirm that spinal dural arteriovenous fistula should be treated as early as possible after diagnosis.

Entities:  

Mesh:

Year:  1999        PMID: 10323315     DOI: 10.1007/s004150050331

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  18 in total

1.  Secondary clinical deterioration after successful embolization of a spinal dural arteriovenous fistula: a plea for prophylactic anticoagulation.

Authors:  J Knopman; W Zink; A Patsalides; H A Riina; Y P Gobin
Journal:  Interv Neuroradiol       Date:  2010-07-19       Impact factor: 1.610

2.  N-butyl 2-cyanoacrylate embolization of spinal dural arteriovenous fistulae: CT evaluation, technical features, and outcome prognosis in 26 cases.

Authors:  Remy Guillevin; J N Vallee; E Cormier; D Lo; D Dormont; J Chiras
Journal:  AJNR Am J Neuroradiol       Date:  2005-04       Impact factor: 3.825

3.  N-butyl 2-cyanoacrylate embolization of spinal dural arteriovenous fistulae.

Authors:  J K Song; Y P Gobin; G R Duckwiler; Y Murayama; J G Frazee; N A Martin; F Viñuela
Journal:  AJNR Am J Neuroradiol       Date:  2001-01       Impact factor: 3.825

4.  Spinal dural arteriovenous fistula: a case series and review of imaging findings.

Authors:  Shandy Fox; Luke Hnenny; Uzair Ahmed; Kotoo Meguro; Michael E Kelly
Journal:  Spinal Cord Ser Cases       Date:  2017-07-06

5.  Clinical and Radiologic Characteristics of Deep Lumbosacral Dural Arteriovenous Fistulas.

Authors:  F Jablawi; O Nikoubashman; G A Schubert; M Dafotakis; F-J Hans; M Mull
Journal:  AJNR Am J Neuroradiol       Date:  2017-12-28       Impact factor: 3.825

6.  Spinal dural arteriovenous fistulas: clinical experience with endovascular treatment as a primary therapy at 2 academic referral centers.

Authors:  J J Gemmete; N Chaudhary; A E Elias; A K Toma; A S Pandey; R A Parker; I Davagnanam; C O Maher; S Brew; F Robertson
Journal:  AJNR Am J Neuroradiol       Date:  2013-04-25       Impact factor: 3.825

7.  Clinical Characteristics and Treatment Outcomes of Spinal Arteriovenous Malformations.

Authors:  Ji Eun Park; Hae-Won Koo; Hairi Liu; Seung Chul Jung; Danbi Park; Dae Chul Suh
Journal:  Clin Neuroradiol       Date:  2016-09-13       Impact factor: 3.649

8.  Spinal dural arteriovenous fistula with supply from the lateral sacral artery-case report and review of literature-.

Authors:  Kwan-Woong Park; Sung Il Park; Soo-Bin Im; Bum-Tae Kim
Journal:  J Korean Neurosurg Soc       Date:  2009-02-28

9.  Endovascular management of spinal dural arteriovenous fistulas in 78 patients.

Authors:  M Kirsch; E Berg-Dammer; C Musahl; H Bäzner; D Kühne; H Henkes
Journal:  Neuroradiology       Date:  2013-01-19       Impact factor: 2.804

10.  Long-term outcome of a multidisciplinary concept of spinal dural arteriovenous fistulae treatment.

Authors:  Camillo Sherif; Andreas Gruber; Gerhard Bavinzski; Harald Standhardt; Georg Widhalm; Daniel Gibson; Bernd Richling; Engelbert Knosp
Journal:  Neuroradiology       Date:  2007-11-20       Impact factor: 2.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.